The research, reported in Frontiers in Cardiovascular Medicine, included consecutive patients with suspected carotid atherosclerosis who were examined at the First Affiliated Hospital of Henan Medical University in China between December 2023 and June 2025. Of 886 people screened, 119 met the eligibility criteria. Fifty-two patients were classified as symptomatic, meaning they had an ipsilateral acute ischemic stroke or transient ischemic attack within the preceding two weeks, and 67 were classified as asymptomatic. A senior neurologist established the diagnoses using symptoms, time of onset and imaging. The mean age was 64.61 years, and 78 participants were male. Symptomatic patients were more likely to have hypertension and a history of smoking, while the groups did not differ significantly in age, sex distribution, body mass index, hyperlipidemia, coronary heart disease or diabetes.

Researchers used a three-phase carotid computed tomography angiography protocol that included unenhanced images, an arterial phase and delayed imaging acquired 90 seconds after iodinated contrast administration. Artificial-intelligence-assisted flexible registration and differential subtraction were then used to create black-blood CT images. This processing suppresses the high-density contrast inside the vessel lumen while retaining delayed enhancement in the vessel wall and plaque, improving the visibility of non-calcified plaque components. A lipid-rich necrotic core was defined as occupying more than 40% of the total plaque area. In parallel, investigators manually placed regions of interest in the perivascular adipose tissue on the unenhanced images, at least 1 mm beyond the outer arterial wall and away from the lumen and nearby bone. Each measurement was repeated three times, and the maximum and mean attenuation values were recorded in Hounsfield units.

The imaging measurements proved highly reproducible. Intraclass correlation coefficients for maximum perivascular fat density were 0.937 for repeat readings by the same observer and 0.859 between observers; for mean density, the corresponding values were 0.899 and 0.842. Radiologists also had excellent agreement when deciding whether a plaque contained a lipid-rich necrotic core, with a kappa value of 0.834. This reliability is important because the proposed use of fat density depends on obtaining consistent measurements from small regions of adipose tissue. It does not, however, establish that the method will perform similarly across other hospitals, scanners or broader patient populations.

Symptomatic patients had substantially more severe and more complex plaque. Their median stenosis was 21.37%, compared with 7.69% in asymptomatic patients, and their mean plaque burden was 72.50% rather than 55.92%. Maximum plaque thickness, eccentricity and the remodeling index were also higher. Lipid-rich necrotic core plaques were present in 47 of 52 symptomatic patients, or 90.4%, but in only 11 of 67 asymptomatic patients, or 16.4%. The groups also differed in vascular geometry: symptomatic patients had a smaller carotid common-to-internal artery angle, a smaller proximal internal carotid curvature angle, a larger bifurcation angle and a higher maximum common carotid artery area ratio. These were group differences, not longitudinal measurements of how geometry changed before an event.

The clearest perivascular signal appeared on the side containing the plaque. Maximum plaque-side fat density averaged -37.95 Hounsfield units in symptomatic patients and -49.74 in asymptomatic patients, while mean density was -59.13 and -68.97, respectively. Less-negative CT attenuation indicates greater density, and the source article interprets this pattern as a possible sign of local perivascular inflammation. Contralateral measurements did not differ significantly between the groups. Within both symptomatic and asymptomatic patients, however, plaque-side density was higher than density on the opposite side, suggesting that the phenomenon was spatially associated with the diseased artery rather than a general difference in the adipose tissue of symptomatic individuals.

Perivascular fat density also rose with several measures of plaque vulnerability. Spearman correlations between maximum fat density and lipid-rich necrotic core presence, plaque burden, eccentricity, stenosis severity, remodeling index and maximum plaque thickness were all positive, with reported p-values below 0.001. The strongest correlations involved the presence of a lipid-rich necrotic core: the correlation coefficient was 0.729 for maximum density and 0.782 for mean density. The proposed biological explanation is that inflamed arterial walls can influence nearby adipose tissue through paracrine signaling, and that this interaction can alter fat composition and increase its CT attenuation. This mechanism remains a hypothesis consistent with the observations, rather than a mechanism directly demonstrated by tissue sampling in this study.

In multivariable logistic regression adjusted for clinical variables, three factors remained independently associated with recent symptomatic status: stenosis severity, with an odds ratio of 1.287 per modeled increase; presence of a lipid-rich necrotic core, with an odds ratio of 10.344; and maximum perivascular fat density, with an odds ratio of 1.196. The confidence interval for the lipid-rich core association was wide, from 1.472 to 72.679, indicating substantial uncertainty around its estimated effect size. Maximum density alone had an optimism-corrected AUC of 0.908, compared with 0.863 for lipid-rich core presence and 0.885 for stenosis. Adding either fat density or lipid-rich core presence to stenosis increased the corrected AUC to 0.971 or 0.966, respectively, but their difference was not statistically significant.

The three-factor model produced the highest internally validated AUC of 0.972, with a 95% confidence interval of 0.944 to 0.995. At its reported optimal cutoff, the model had 94.2% sensitivity and 92.5% specificity for distinguishing symptomatic from asymptomatic patients. Bootstrap comparisons showed that the combined model significantly outperformed the stenosis-only model, with an AUC difference of 0.085 and p=0.002. Calibration analyses suggested that estimated risks agreed reasonably well with observed event rates, and exploratory decision-curve analysis indicated greater net clinical benefit than the stenosis-only model across the evaluated thresholds. These performance measures are promising but remain internal to the dataset: the investigators used 1,000 bootstrap resamples rather than prospective testing or an independent external cohort.

Several limitations constrain how the results should be interpreted. The single-center design allowed selection bias, could not establish whether changes in perivascular fat preceded symptoms and cannot exclude reverse causation. Manual region-of-interest placement prevented volumetric quantification, while the sample was too small for detailed stratified analysis of pre-examination medication use. The comparison benchmark was a stenosis-only model rather than a model containing established clinical risk factors, which may have exaggerated the imaging model’s incremental value. Decision-curve findings were exploratory, residual confounding remained possible, and inclusion of only unilateral atherosclerosis limits applicability to bilateral disease. There was also no histopathological validation or prospective follow-up for future events. The results therefore support perivascular fat density as a promising candidate imaging marker of local vascular inflammation, but not as a validated standalone predictor of stroke.

Subject of Research: Association of CT-measured perivascular fat density with vulnerable carotid plaque and recent ischemic cerebrovascular events

Article Title: Association of perivascular fat density with vulnerable plaque and recent symptomatic cerebrovascular events

Article References: Yue, J.-Y., Liu, H.-P., Li, R., Ji, K., Yin, Z., Ding, S.-G., & Liang, C.-H. (2026). Association of perivascular fat density with vulnerable plaque and recent symptomatic cerebrovascular events. Frontiers in Cardiovascular Medicine, 13, Article 1965601. https://doi.org/10.3389/fcvm.2026.1965601

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1965601

Keywords: perivascular fat density, carotid atherosclerosis, vulnerable plaque, lipid-rich necrotic core, black-blood CT, ischemic stroke, transient ischemic attack, cerebrovascular imaging, plaque inflammation, Association, perivascular, density

The research, led by Chiara Giordano and Giacomo Gamberini of the University of Milan together with senior author Stefano Carugo and a team spanning the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, focused on a measurement called the Left Atrial Volumetric–Mechanical Coupling Index, abbreviated LACI-VM. The index is elegantly simple: it is calculated by dividing the left atrial volume index—the size of the heart’s upper left chamber adjusted for body surface area—by a′, the late diastolic mitral annular velocity measured with Doppler tissue imaging. That denominator reflects how well the atrium contracts during its mechanical squeeze. A large atrium that still contracts vigorously produces a modest ratio; a large, sluggish atrium produces a high one. In other words, LACI-VM fuses two complementary dimensions of atrial disease into a single number obtainable from any standard transthoracic echo.

The rationale is rooted in the biology of atrial cardiomyopathy. When the left atrium is chronically exposed to high filling pressures, hypertension, or aging-related fibrosis, it enlarges and its muscle fibers are progressively replaced by scar tissue. Electrical conduction through this remodeled chamber becomes slow and heterogeneous, creating the substrate for the reentrant circuits that drive atrial fibrillation. Structural dilation alone, captured by the left atrial volume index, has long been known to predict AF detection after cryptogenic stroke. Mechanical dysfunction, assessable through atrial strain or annular velocities, adds independent information. By combining both, LACI-VM aims to capture the full anatomical and functional footprint of an atrium that is primed to fibrillate.

The Milanese team applied this concept to 285 consecutive patients admitted with an embolic stroke or transient ischemic attack of undetermined source. All underwent transthoracic echocardiography during the index hospitalization, including measurement of LACI-VM and of the related Left Atrioventricular Coupling Index, or LACI, which is defined as the ratio of left atrial end-diastolic volume to left ventricular end-diastolic volume and reflects atrioventricular uncoupling. The patients, whose median age was 71 years and of whom 43 percent were women, were then followed for new-onset atrial fibrillation. Over a median follow-up of 10.9 months, AF appeared in 24 patients, or 8.4 percent of the cohort—and, critically, 62 percent of those events occurred within the first year, underscoring how early the arrhythmia tends to declare itself after a cerebral embolic event.

The statistical results were striking. LACI-VM was significantly higher in patients who went on to develop atrial fibrillation, and after multivariable adjustment for confounders it remained independently associated with incident AF, with a hazard ratio of 6.64 and a confidence interval of 1.34 to 59.88, reaching a p-value of 0.041. A hazard ratio approaching seven means that patients with an impaired coupling index faced roughly a six- to seven-fold higher rate of AF detection than their counterparts with preserved values, a magnitude of effect rarely seen for a single echocardiographic parameter. By contrast, the purely volumetric LACI showed only a non-significant overall association, with a hazard ratio of 2.28 and a p-value of 0.09, and its predictive power appeared confined to events occurring within the first twelve months. The comparison suggests that atrial mechanical performance, not merely chamber size, carries the prognostic signal that matters for unmasking occult AF.

Perhaps the most clinically actionable finding emerged when the researchers combined LACI-VM with an assessment of left ventricular filling pressures, expressed as the E/e′ ratio—the ratio of early transmitral flow velocity to early diastolic mitral annular velocity. Patients whose LACI-VM remained below 2.5 and whose E/e′ was 10 or lower experienced an AF incidence of only about 2 percent, identifying a genuinely low-risk subgroup in whom intensive, invasive rhythm monitoring may be safely deferred. At the opposite extreme, when both the coupling index was elevated at 2.5 or above and filling pressures were elevated above 10, the AF risk climbed to roughly 20 percent—a tenfold difference between the two phenotypes. This layered approach transforms a single ultrasound number into a practical decision tool: one echo study, performed during the index admission, can separate stroke survivors who need implantable loop recorders from those who can be managed with conventional, less burdensome surveillance.

The implications reach into one of the most contested corners of stroke medicine. Randomized trials such as CRYSTAL-AF and FIND-AF, which used implantable or prolonged monitoring, established that occult atrial fibrillation is common after cryptogenic stroke, detecting it in a meaningful fraction of patients over months to years. Yet prolonged monitoring is costly, and debates persist about how intensively every ESUS patient should be screened, whether oral anticoagulation benefits all detected subgroups, and how to weigh the burden of devices against the risk of recurrent embolism. European Society of Cardiology consensus statements have repeatedly called for better tools to stratify patients. An index that costs nothing beyond an echocardiogram already being performed fits that need precisely, potentially concentrating expensive monitoring resources on the patients most likely to benefit.

The study also builds on a growing literature. LACI-VM was first proposed as a predictor of outcomes in heart failure with reduced ejection fraction, and subsequent work has linked atrioventricular coupling indices to cardiovascular events in the Multi-Ethnic Study of Atherosclerosis, to new-onset AF in hypertrophic cardiomyopathy, and to heart failure and AF in the general population. Earlier investigations specifically in ESUS populations reported that the volumetric-mechanical coupling index associated with AF detection, and the Milan group itself had previously shown that peak atrial longitudinal strain can catch atrial fibrillation in sinus-rhythm patients admitted for cerebral ischemic events. The present analysis extends this line by demonstrating independent prediction in a dedicated ESUS and TIA cohort and by pairing the index with filling pressures to define a truly low-risk stratum.

Certain caveats temper the enthusiasm. The investigation was retrospective and conducted at a single center, and the confidence interval around the hazard ratio is wide, reflecting the modest number of endpoint events; larger, prospective, multicenter validation will be needed before the index enters guidelines. The follow-up duration of roughly eleven months captures the early window in which most events occurred but may miss later arrhythmia emergence. Still, the direction of the evidence is coherent with atrial physiology, the measurement is reproducible with standard techniques endorsed by the American Society of Echocardiography and the European Association of Cardiovascular Imaging, and the effect sizes are large enough to be clinically meaningful even in a small cohort.

For patients and clinicians alike, the message is compelling. A stroke whose cause remains invisible may not be invisible to the heart itself: the left atrium often carries the fingerprints of the arrhythmia that launched the clot. By reading those fingerprints through a simple ratio of atrial size to atrial squeeze, obtained from an ultrasound exam already part of routine care, physicians may soon be able to tailor rhythm monitoring with far greater precision—intensifying surveillance for the one in five patients at highest risk while sparing the many at genuinely low risk from unnecessary devices and prolonged uncertainty. In a field where every undetected episode of atrial fibrillation represents a potential second, potentially devastating stroke, a cheap, fast, and widely available predictor is exactly the kind of advance that could change practice.

Subject of Research: Prediction of early new-onset atrial fibrillation after embolic stroke or TIA of undetermined source using echocardiographic left atrial volumetric–mechanical coupling indices

Article Title: Echocardiography-derived Left Atrial Volumetric–Mechanical Coupling Index predicts early new-onset atrial fibrillation after embolic stroke/transient ischemic attack of undetermined source

Article References: Giordano, C., Gamberini, G., Faggiano, A., Garau, L., Conti, G., D’Andria, P. F., Moda, F., Mallardi, G., Saviano, M., Bonato, S., Ghione, I., Lanfranconi, S., Gherbesi, E., Santangelo, G., Ruscica, M., Bursi, F., & Carugo, S. (2026). Echocardiography-derived Left Atrial Volumetric–Mechanical Coupling Index predicts early new-onset atrial fibrillation after embolic stroke/transient ischemic attack of undetermined source. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03041-y

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03041-y

Keywords: atrial fibrillation, embolic stroke of undetermined source, echocardiography, left atrium, LACI-VM, left atrioventricular coupling index, transient ischemic attack, rhythm monitoring, implantable loop recorder, atrial cardiomyopathy, E/e′ ratio, stroke prevention

The research, led by Xinya Li and colleagues including Anxin Wang, drew on the Third China National Stroke Registry, one of the largest and most rigorously maintained stroke databases in the world. Between 2015 and 2018, the registry enrolled consecutive adult patients admitted to participating hospitals with a diagnosis of ischemic stroke, in which a blood clot blocks flow to part of the brain, or transient ischemic attack, a temporary interruption of blood supply that often precedes a full stroke. From this population, the investigators identified 2,859 patients who left the hospital with a prescription for either amlodipine or nifedipine and who could be followed for five years afterward.

The question the team posed was deceptively simple: did patients taking one drug fare better than patients taking the other? But answering it in an observational setting, where doctors choose medications rather than a computer randomizing them, requires sophisticated statistical machinery. The researchers’ primary yardstick was the modified Rankin Scale, or mRS, a standard clinical tool that grades functional outcomes after stroke on a spectrum from zero, meaning no symptoms at all, to six, indicating death. Rather than collapsing this scale into crude categories, the team analyzed the full distribution of scores using ordinal logistic regression, a method that preserves the ordered nature of disability levels and yields an odds ratio describing the odds of being at a better rather than a worse point on the scale.

Because patients prescribed amlodipine might differ systematically from those given nifedipine, in age, sex, body mass index, blood pressure on admission, or timing of their stroke, the researchers applied inverse probability of treatment weighting, a technique that statistically reweights the two groups to mimic the balance achieved in a randomized trial. After this adjustment, the analytic cohort comprised 1,847 patients on amlodipine and 1,058 on nifedipine, with baseline characteristics aligned across the two groups. The models also adjusted for age, gender, body mass index, admission systolic blood pressure, and the date of symptom onset, guarding against confounding from calendar-time changes in stroke care.

The results pointed in one direction. Patients discharged on amlodipine showed significantly better functional outcomes at five years than those on nifedipine, with an odds ratio of 0.76 for worse mRS scores, a 95 percent confidence interval of 0.65 to 0.89, and a p-value below 0.001. Put more concretely, 51.76 percent of amlodipine users, 956 patients, had at least some residual disability or worse, an mRS score above zero, at five years, compared with 59.74 percent of nifedipine users, 632 patients. The corresponding odds ratio of 0.71, with a confidence interval of 0.61 to 0.83, indicates that the odds of avoiding disability were meaningfully higher in the amlodipine group. Sensitivity analyses, which test whether the findings survive alternative statistical assumptions, produced consistent results throughout.

What could explain such a divergence between two drugs that lower blood pressure through the same basic mechanism? Calcium channel blockers work by blocking L-type calcium channels in vascular smooth muscle, preventing calcium ions from entering these cells and thereby relaxing arterial walls. Nifedipine is a first-generation dihydropyridine with a short half-life in its immediate-release form, producing rapid vasodilation that can trigger reflex activation of the sympathetic nervous system, surges of heart rate, and oscillating blood pressure. Amlodipine, by contrast, has a long half-life of roughly 30 to 50 hours, producing gradual, sustained vasodilation with minimal peak-to-trough fluctuation. For a brain already injured by ischemia, the stability of perfusion pressure may be critical; sharp swings in blood pressure can stress impaired cerebral autoregulation, the mechanism by which brain blood vessels maintain constant flow despite systemic changes. The authors note that these pharmacological differences, along with amlodipine’s longer duration of action and smoother pharmacokinetic profile, could plausibly underlie the observed advantage, though the study design cannot prove causation.

The stakes of this question are enormous. Stroke remains a leading cause of death and long-term disability worldwide, and China bears a particularly heavy burden, with ischemic stroke accounting for the majority of the roughly four million new strokes recorded there each year. Secondary prevention after a stroke or TIA hinges on controlling vascular risk factors, and blood pressure management is the single most powerful modifiable lever. Because amlodipine and nifedipine are among the most commonly prescribed antihypertensives for these patients, and because they are often treated as clinically equivalent members of the same drug class, even a modest real difference in five-year functional outcomes would translate into substantial population-level effects if prescribing patterns shifted toward the better-performing agent.

The authors are careful to frame their findings as hypothesis-generating rather than practice-changing. As an observational study, it inherits the inherent limitations of registry data: physicians chose which drug to prescribe, and despite the statistical balancing achieved through weighting, unmeasured differences between the groups could still have influenced outcomes. The exclusive reliance on registry records limits the granularity of clinical information available, and the loss to follow-up at five years was relatively high, a common challenge in long-term cohort studies that can bias results if attrition differs between groups. These caveats do not erase the signal, which was robust across sensitivity analyses, but they mean the findings stop short of the evidentiary standard that typically guides prescribing decisions.

The path forward, the researchers argue, runs through randomized controlled trials, in which patients with ischemic stroke or TIA would be assigned by chance to amlodipine or nifedipine and followed prospectively. Such trials would eliminate the confounding that shadows any observational comparison and could also probe intermediate mechanisms, including ambulatory blood pressure variability, sympathetic activation, and markers of cerebral small-vessel health. Until then, the study stands as a striking reminder that drugs within the same class are not interchangeable, and that the quiet, long-acting pharmacology of amlodipine may offer stroke survivors something nifedipine does not: a steadier road to recovery measured not in days or months, but in the fullness of five years of life after the brain has been injured.

Subject of Research: Comparative effectiveness of amlodipine versus nifedipine at discharge after ischemic stroke or transient ischemic attack

Article Title: Comparative effectiveness of amlodipine versus nifedipine prescribed at discharge in patients with ischemic stroke or transient ischemic attack: A nationwide 5-year follow-up registry study

Article References: Li, X., Xia, X., Gao, M., Xu, Q., Zhang, Y., Jing, J., Zhai, Y., Meng, X., & Wang, A. (2026). Comparative effectiveness of amlodipine versus nifedipine prescribed at discharge in patients with ischemic stroke or transient ischemic attack: A nationwide 5-year follow-up registry study. PLOS Medicine, 23(10), e1005277. https://doi.org/10.1371/journal.pmed.1005277

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005277

Keywords: amlodipine, nifedipine, calcium channel blockers, ischemic stroke, transient ischemic attack, blood pressure, functional outcome, modified Rankin Scale, stroke registry, secondary prevention, pharmacology, observational study

The study enrolled 334 patients who had suffered what the researchers classify as high-risk non-disabling ischemic cerebrovascular events, abbreviated HR-NICE. This category covers transient ischemic attacks and minor strokes that do not leave patients disabled but carry a high probability of recurrence. The danger window is brutally short: the risk of another vascular event is highest within the first days and weeks after the initial episode, which is precisely when early neurological deterioration tends to strike. Patients were enrolled within 24 hours of symptom onset — a demanding logistical requirement that reflects how rapidly the therapeutic window closes. Once enrolled, they were randomly assigned in a one-to-one ratio to one of two dual antiplatelet regimens: low-dose ticagrelor at 60 milligrams twice daily plus aspirin, or clopidogrel plus aspirin.

The logic behind the comparison rests on a well-known weakness of clopidogrel. The drug is a prodrug, meaning it must be converted by liver enzymes into its active form before it can inhibit platelets. The critical enzyme, CYP2C19, is encoded by a gene that varies widely between individuals. People carrying so-called loss-of-function alleles — a variant that is especially common in East Asian populations, affecting a majority of Chinese patients — convert clopidogrel poorly or not at all. For these patients, standard clopidogrel-based therapy offers substantially weaker platelet inhibition, and previous studies have linked poor clopidogrel response to early neurological deterioration after acute ischemic stroke. Ticagrelor, by contrast, is a reversible P2Y12 receptor antagonist that does not require metabolic activation, so its antiplatelet effect is essentially independent of CYP2C19 genotype.

This pharmacological distinction has already reshaped stroke care in China. The CHANCE-2 trial, published in the New England Journal of Medicine in 2021, showed that in patients carrying CYP2C19 loss-of-function alleles, ticagrelor plus aspirin outperformed clopidogrel plus aspirin in preventing recurrent stroke within 90 days. But CHANCE-2 required rapid genotyping to identify carriers — a capability that many hospitals, particularly in resource-limited settings, simply do not have. The new trial was designed with this gap in mind. Rather than genotyping patients and treating only those with the resistant variant, the investigators asked a more pragmatic question: does low-dose ticagrelor beat clopidogrel in an unselected HR-NICE population, where a large proportion of patients would be expected to carry loss-of-function alleles?

The answer was a clear yes. Early neurological deterioration within seven days — defined as an increase of at least two points on the National Institutes of Health Stroke Scale, or a one-point increase in the motor subscore compared with baseline — occurred in 10.8 percent of patients receiving ticagrelor plus aspirin, compared with 22.2 percent of those receiving clopidogrel plus aspirin. That corresponds to a relative risk of 0.55, with a 95 percent confidence interval of 0.33 to 0.92 and a p-value of 0.023. In plain terms, the ticagrelor regimen roughly halved the odds that a patient’s neurological condition would worsen in the critical first week. The trial used an intention-to-treat analysis, the most conservative approach, and its open-label design with blinded endpoint adjudication means that while treating physicians knew which drugs patients received, the researchers assessing outcomes did not — a design that minimizes bias in the primary result.

The benefits extended well beyond the first week. At 90-day follow-up, 92.8 percent of patients in the ticagrelor group had achieved an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale, the standard measure of post-stroke disability. In the clopidogrel group, the figure was 80.8 percent — a statistically significant difference, with a relative risk of 1.13 and a p-value of 0.002. The rate of major ischemic vascular events within 90 days also trended in favor of ticagrelor, at 6.6 percent versus 10.8 percent, though this difference did not reach statistical significance (relative risk 0.54; p = 0.085), likely reflecting the relatively small number of events in a trial of this size.

Just as important as the efficacy signal was the safety profile, because the perennial concern with intensified antiplatelet therapy is bleeding. Dual antiplatelet regimens walk a narrow line: they must suppress platelet aggregation enough to prevent clot propagation and recurrence, but not so much that spontaneous hemorrhage becomes a hazard. In this trial, any bleeding events occurred in 6.0 percent of the ticagrelor group versus 4.2 percent of the clopidogrel group — a difference that was neither statistically significant (p = 0.563) nor clinically alarming, particularly since all bleeding events in both groups were classified as mild. Rates of adverse events overall (12.6 percent versus 10.2 percent) and serious adverse events (0.6 percent versus 1.8 percent) were similarly balanced between the groups. The low 60-milligram twice-daily dose of ticagrelor, rather than the 90-milligram dose used in cardiac patients, appears to be the key to achieving potent platelet inhibition while keeping bleeding in check.

The trial’s design details reinforce the credibility of these findings. It was registered prospectively with the Chinese Clinical Trial Registry in February 2023, conducted across multiple centers, and approved by the ethics committee of the First Affiliated Hospital of Dalian Medical University, with all patients or their legal representatives providing written informed consent. The investigators adhered to the Declaration of Helsinki and Good Clinical Practice guidelines. The primary endpoint — early neurological deterioration — is a mechanistically meaningful outcome, because it captures the dynamic process of thrombus growth and new clot formation in the vulnerable cerebral circulation, rather than merely counting later recurrent strokes. By targeting this early window, the regimen intervenes at the moment when platelet-rich thrombi are most actively propagating.

Why does the result matter globally, and not only in China? The CYP2C19 loss-of-function variant is most prevalent in East Asian populations, but it is common elsewhere too, and clopidogrel resistance is a recognized problem wherever the drug is used. Moreover, the trial’s most practical implication is precisely that it does not require genotyping. The authors conclude that the regimen may provide a safe and effective alternative antiplatelet strategy for preventing early neurological deterioration in institutions lacking rapid genotyping facilities — a description that fits the majority of stroke centers worldwide. A physician confronting a patient with a high-risk minor stroke or TIA can start low-dose ticagrelor plus aspirin immediately, without waiting for genetic test results that may take days or simply be unavailable.

Cautions remain, as they always do with a single trial. The study was conducted in China, the sample size of 334 patients is modest, and the open-label design, while mitigated by blinded endpoint assessment, cannot eliminate all performance bias. The trend toward fewer ischemic vascular events at 90 days did not reach statistical significance, and longer-term outcomes beyond three months were not assessed. Broader international replication, ideally in populations with different baseline risks and genetic backgrounds, would strengthen the evidence base. Still, the magnitude of the effect on early deterioration — the single most feared event in the days after a minor stroke — combined with a clean bleeding profile, makes this one of the more consequential antiplatelet findings in recent stroke research. For patients in the fragile hours after a warning stroke, a cheap, widely available, genotype-independent drug combination that halves the risk of getting worse is exactly the kind of pragmatic advance that changes clinical practice.

Subject of Research: Low-dose ticagrelor plus aspirin versus clopidogrel plus aspirin for preventing early neurological deterioration after high-risk non-disabling ischemic cerebrovascular events

Article Title: Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial

Article References: Liu, J., Cao, H., Wang, M., Jiao, Y., Zhou, R., Tang, Y., Chen, R., Liu, X., Shen, J., Li, D., Tian, W., Gong, X., Zhang, B., Liu, Y., & Ji, X. (2026). Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial. Journal of Neurology, 273(10), Article 568. https://doi.org/10.1007/s00415-026-14094-4

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14094-4

Keywords: ticagrelor, aspirin, clopidogrel, early neurological deterioration, minor stroke, transient ischemic attack, dual antiplatelet therapy, CYP2C19, randomized clinical trial, stroke prevention, P2Y12 inhibitor, functional outcome

The research, led by Francesco Berinato and colleagues at the University of Brescia and ASST Spedali Civili Hospital in Italy, focused on two proteins that have become central to the emerging field of blood-based neurology: neurofilament light chain, abbreviated NfL, and glial fibrillary acidic protein, known as GFAP. NfL is a structural component of the long, cable-like projections of neurons, and when axons are injured, fragments of this protein leak into the surrounding fluid and eventually reach the bloodstream. GFAP, by contrast, is a scaffolding protein found in astrocytes, the star-shaped support cells of the brain, and it rises when these glial cells are damaged or activated. Because each protein reports on a different cellular population, measuring both together provides a two-channel view of brain injury, capturing damage to neurons and to their supporting architecture simultaneously.

The technical challenge has always been sensitivity. Concentrations of NfL and GFAP in blood are vanishingly small, measured in picograms per milliliter, or trillionths of a gram. Conventional immunoassays simply could not detect these levels reliably in plasma. The Brescia team turned to single molecule array technology, or Simoa, an ultrasensitive digital detection platform that counts individual protein molecules by trapping them in microscopic wells studded with magnetic beads and reading out fluorescent signals one bead at a time. This approach, which has transformed research into neurodegenerative disease, made it possible to quantify subtle elevations in proteins released by microscopic, transient brain injury that no scanner can see.

The study design was deliberately conservative. The researchers enrolled 36 patients who had experienced a clinically defined TIA but whose brain MRI showed no infarct, meaning no visible stroke lesion. Each patient was matched by age and sex to two healthy controls, yielding a comparison group of 72 individuals. Blood samples were drawn within 24 hours of hospital admission, a window chosen to capture proteins while injury-related release was still at or near its peak. The team then performed group comparisons, constructed receiver operating characteristic curves to identify optimal diagnostic thresholds, and ran a series of sensitivity analyses designed to strip out confounding factors that could artificially inflate biomarker levels.

The results were striking. Patients with MRI-negative TIA had plasma NfL concentrations averaging 27.22 picograms per milliliter, more than two and a half times the control average of 10.44 picograms per milliliter, a difference that was highly statistically significant. GFAP told a similar story, averaging 301.99 picograms per milliliter in patients versus 131.65 in controls. In other words, even when the brain looked perfectly normal on imaging, the blood carried a chemical record of injury. The findings held up when the researchers systematically excluded patients with pre-existing disability, previous stroke or TIA, impaired kidney function, a heavy burden of small vessel disease on MRI, and moderate to severe cortical atrophy, all conditions known to raise NfL or GFAP independently of any acute event.

The diagnostic performance of each marker revealed an interesting asymmetry. The optimal cutoff for NfL was 16.83 picograms per milliliter, a threshold that achieved remarkable specificity of 98.6 percent, meaning that almost no healthy individual exceeded it, but sensitivity of only 52.8 percent, meaning it flagged only about half of the TIA patients. GFAP at a cutoff of 179.23 picograms per milliliter was more balanced, with sensitivity of 69.4 percent and specificity of 81.9 percent. The most powerful result emerged when the two proteins were interpreted together. A combined assessment raised sensitivity to 80.6 percent while preserving specificity at 81.9 percent, and produced the highest discriminative accuracy of any configuration tested, with an area under the curve of 0.812. The complementary biology makes sense of this: axonal injury and astroglial activation are partially independent processes, so a patient whose injury is too subtle to push one marker over threshold may still push the other.

Why does this matter clinically? TIA is fundamentally a warning sign, a brief interruption of blood flow that predicts a substantial risk of subsequent full stroke, particularly in the days and weeks that follow. Current guidelines rely on clinical scoring systems, imaging to exclude stroke mimics, and urgent vascular workup to stratify risk. But a substantial fraction of suspected TIAs remain diagnostically ambiguous, especially when imaging is negative and symptoms have fully resolved. Objective blood markers could help confirm that a transient neurological event genuinely reflected brain ischemia rather than a mimic such as migraine aura, seizure, or peripheral vestibular disorder. They could also, in principle, help quantify the tissue impact of the event, complementing what imaging cannot show.

The broader context is a field in rapid motion. Prior work has established that NfL rises acutely after overt ischemic stroke, correlates with stroke severity, and predicts functional outcome, and a recent individual patient data meta-analysis consolidated the diagnostic and prognostic value of blood NfL in ischemic stroke. GFAP has shown promise in distinguishing stroke types and mapping the timeline of tissue impact after acute cerebrovascular events. What the Brescia study adds is a crucial piece of that puzzle: evidence that the biomarker signal is not merely a byproduct of large, scan-visible infarcts, but reflects genuine microscopic injury even in the mildest end of the ischemic spectrum. This aligns with a growing recognition that TIA is not a benign non-event but a real injury whose consequences, including subtle cognitive decline after first-time TIA, may be underestimated by conventional imaging.

Important caveats remain, and the authors are careful to acknowledge them. The study was single-center and retrospective, with a modest sample of 36 patients, and the control group, while carefully matched, cannot capture the full diversity of patients who present to emergency departments with TIA-like symptoms. Specificity figures derived from healthy controls will likely look different against real-world differential diagnoses, where conditions such as renal impairment, trauma, and neurodegenerative disease can elevate the same proteins. The sensitivity analyses go a long way toward addressing these concerns, but the authors themselves state that larger studies are needed to confirm clinical utility before such tests enter routine practice.

Even so, the trajectory is clear. Blood-based biomarkers are moving from the research bench toward the stroke unit, propelled by ultrasensitive platforms like Simoa and by accumulating evidence across the cerebrovascular disease spectrum. A simple blood draw taken within a day of a suspected TIA, interpreted alongside clinical scores and imaging, could one day transform one of neurology’s most uncertain diagnoses into a measurable, quantifiable event. For patients who are told their scan is clean but their symptoms were real, the blood may soon provide the answer that the scanner cannot, confirming that even the briefest storm in the brain leaves its mark, written in the language of proteins, detectable in a few milliliters of plasma.

Subject of Research: Blood biomarkers NfL and GFAP for detecting microscopic brain injury in MRI-negative transient ischemic attack

Article Title: Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP

Article References: Berinato, F., Morotti, A., Baronchelli, G., Tolassi, C., Girotto, I., Pilotto, A., & Padovani, A. (2026). Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. Journal of Neurology, 273(10), Article 580. https://doi.org/10.1007/s00415-026-14097-1

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14097-1

Keywords: transient ischemic attack, TIA, neurofilament light chain, GFAP, blood biomarkers, brain injury, stroke, Simoa, MRI, neurology, cerebrovascular disease, plasma biomarkers

A new real-world study published in the Journal of Neurology by Alessia Bellotti of the Neurocenter of Southern Switzerland and colleagues now offers some of the most direct long-term evidence to date. Drawing on a prospective registry of migraine patients treated at a tertiary Headache Centre, the team identified every patient treated with CGRP pathway inhibitors who also carried a documented history of ischemic stroke, transient cerebral ischemic attack, or ischemic heart disease. Out of 420 consecutive patients in the registry, 17 individuals, roughly 4 percent, met these criteria and formed the study cohort. The number is small, but the clinical stakes are not, because each of these patients represents the exact scenario in which prescribing decisions have historically been made with the least data and the greatest uncertainty.

The biology behind the concern is worth unpacking. CGRP is not exclusively a migraine molecule; it is a potent vasodilator and neuropeptide distributed throughout the peripheral and central nervous systems, including the cerebral and coronary vasculature. Under physiological conditions it contributes to the regulation of vascular tone, and experimental work has suggested that CGRP may even play a protective role during cerebral ischemia and reperfusion injury. Blocking this pathway with a monoclonal antibody or a receptor antagonist could, in theory, blunt these protective mechanisms, particularly in vessels already compromised by atherosclerosis or prior infarction. This theoretical risk is amplified in patients whose brains have already demonstrated vulnerability to ischemia, since recurrent stroke carries a substantial cumulative risk, and cardiovascular guidelines emphasize aggressive secondary prevention in exactly this group.

Epidemiology deepens the dilemma rather than resolving it. Large prospective cohort studies have shown that migraine, particularly migraine with aura, is associated with an elevated risk of ischemic stroke in middle-aged and elderly populations, and neuroimaging research has linked migraine to deep white matter lesions and subclinical posterior circulation infarcts. Genetic studies reinforce the connection between migraine and stroke biology. In other words, the migraine patients most likely to have suffered a prior vascular event are not an incidental subgroup; they are the population in whom the migraine-vascular relationship is most pronounced. Denying them the most effective preventive therapies available would leave them exposed to the disabling consequences of chronic migraine, while prescribing without safety data would constitute an uncontrolled experiment. The Swiss registry study was designed to begin filling precisely this evidentiary gap.

The cohort itself reflects the clinical reality of severe, treatment-resistant migraine. The 17 patients had a median age of 54.5 years, 76 percent were women, and 82 percent suffered from chronic migraine, the most disabling form of the disorder, defined by headache on 15 or more days per month. The group accumulated a total of 31 patient-years of exposure to CGRP pathway inhibitors, with individual follow-up extending up to five years. Importantly, the median interval between the original ischemic event and the start of CGRP-targeted treatment was 5.0 years, with an interquartile range of 4.5 years, meaning that most patients were not treated in the immediate aftermath of a stroke or cardiac event but at a point when their vascular disease had been medically stabilized.

The efficacy findings were striking. Thirteen of the 17 patients, 76 percent, achieved a reduction of at least 50 percent in their monthly migraine days, a threshold widely regarded as a clinically meaningful response. Among the 14 patients with chronic migraine, 10 reached this benchmark, and remarkably, all three patients with episodic migraine did so as well. These response rates compare favorably with those reported in broader real-world cohorts of migraine patients without vascular comorbidity, suggesting that a history of stroke or ischemic heart disease does not blunt the therapeutic benefit of CGRP blockade. For patients who had often exhausted multiple conventional preventives, the magnitude of improvement represents a transformation in daily functioning and quality of life.

On the safety side, the results were equally notable for what the investigators did not find. Across the entire follow-up period, no recurrent cerebrovascular events were observed, and no worsening of underlying cardiac disease was documented. In a subset of patients, serial neuroimaging was performed, and dedicated neuroradiological assessment revealed no new ischemic lesions. This combination of clinical and radiological surveillance is significant, because silent ischemic lesions can occur without overt symptoms, and their absence on imaging provides a more sensitive measure of cerebrovascular integrity than clinical history alone. The involvement of a dedicated neuroradiologist, who assessed ischemic lesions using specialized software, adds technical rigor to the imaging component of the study.

The authors are careful, and rightly so, to frame these findings as exploratory and hypothesis-generating rather than definitive. Seventeen patients and 31 patient-years of exposure cannot exclude a modest increase in vascular risk, and the absence of a control group means that the background rate of recurrent events in comparable untreated patients cannot be formally compared. Registry data from a single tertiary center may also be subject to selection effects, since patients considered for CGRP therapy after a stroke are likely to have been judged clinically stable by their treating physicians. Nevertheless, the study aligns with a growing body of real-world evidence, including multicenter safety evaluations of CGRP-targeting antibodies in patients with comorbidities excluded from trials, analyses of cardiovascular safety in older adults, and large pharmacoepidemiological studies examining cardiovascular events among migraine patients exposed to these drugs.

The report also touches on one of the most debated corner cases in the field: CADASIL, a hereditary small-vessel disease characterized by subcortical infarcts and leukoencephalopathy, in which CGRP has been hypothesized to play a protective vascular role. The Swiss registry included a CADASIL case among its patients, and prior case reports have described long-term treatment with the receptor antagonist erenumab in CADASIL without apparent harm, even as commentators have warned about the potential danger of blocking CGRP in such patients. By contributing longitudinal, imaging-verified data from this rare and theoretically highest-risk scenario, the study adds a valuable data point to an ongoing conversation about whether CGRP inhibition is safe in small-vessel cerebrovascular disease.

For clinicians, the practical message is one of cautious reassurance. In patients with prior ischemic stroke, transient ischemic attack, or ischemic heart disease whose vascular disease is stable, CGRP pathway inhibitors appear, on current real-world evidence, to deliver their expected efficacy without detectable clinical or radiological ischemic consequences over follow-up periods of up to five years. This does not eliminate the need for individualized risk assessment, coordination with vascular specialists, and continued surveillance, particularly in the early years after an ischemic event, where the evidence remains sparse. But it does shift the default conversation from whether these drugs can be used at all to how best to monitor them. For the large population of migraine patients living with the dual burden of severe headache and established vascular disease, that shift, however incremental, is genuinely good news, and it underscores the value of prospective registries in answering the safety questions that randomized trials were never designed to address.

Subject of Research: Long-term cerebrovascular and cardiovascular safety of CGRP pathway inhibitors in migraine patients with prior ischemic events

Article Title: Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease

Article References: Bellotti, A., Noseda, R., Masciullo, R., Staedler, C., Gobbi, C., & Zecca, C. (2026). Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease. Journal of Neurology, 273(10), Article 595. https://doi.org/10.1007/s00415-026-14099-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14099-z

Keywords: CGRP, migraine, stroke, ischemic heart disease, monoclonal antibodies, cerebrovascular safety, CADASIL, real-world registry, neuroimaging, preventive treatment, transient ischemic attack, Journal of Neurology

A new study published in Archives of Osteoporosis now offers the most detailed portrait yet of what happens to bone in the immediate aftermath of a cerebral ischemic event. In the baseline analysis of the Post-stroke Osteopathy study, a team led by researchers at the Medical University of Innsbruck in Austria combined high-resolution peripheral quantitative computed tomography, or HR-pQCT, with an extensive panel of biochemical bone markers in a cohort of acute stroke and TIA patients. According to the investigators, this is the largest cohort of ischemic stroke or TIA patients ever examined prospectively with HR-pQCT and the first study anywhere to correlate bone biomarkers with high-resolution imaging parameters in this clinical setting.

The imaging technique at the heart of the study represents a major leap beyond conventional bone assessment. Dual-energy X-ray absorptiometry, the workhorse of osteoporosis screening, measures bone mass in two dimensions and misses critical information about bone quality. HR-pQCT, by contrast, resolves the three-dimensional microarchitecture of cortical and trabecular bone at peripheral sites such as the distal radius and distal tibia with an impressive 61-micrometer voxel size and very low radiation exposure. This matters because bone strength depends not merely on how much mineral bone contains but on its morphology and microstructure, a fact convincingly established by large international consortia showing that cortical and trabecular microarchitecture independently predict fracture risk in older women and men.

In the study, 122 participants were enrolled between March 2021 and May 2022 at the University Hospital Innsbruck as a pilot sub-study of the ongoing STROKE-CARD Registry. Of these, 116 underwent baseline HR-pQCT imaging of all four extremities within days of their event, with a median age of 71.5 years and 26.7 percent women. Neurological deficits were predominantly mild, reflected by a median National Institutes of Health Stroke Scale score of 2, and scans were performed on average 5.4 days after admission. Blood samples for biomarker analysis were drawn in 62 patients a mean of 3.0 days after admission and analyzed using validated enzyme-linked immunosorbent assays for osteocalcin, C-telopeptide of crosslinked collagen type 1, sclerostin, osteoprotegerin, soluble RANKL, and periostin.

The imaging results revealed clear patterns. Women in the cohort had lower total, cortical, and trabecular volumetric bone mineral density, along with lower values for nearly every other HR-pQCT parameter, in both the upper and lower extremities. This finding mirrors what has been documented in healthy reference populations, suggesting that stroke patients retain normal sex-based differences in bone structure. Increasing age was associated with lower total and cortical volumetric bone mineral density, but intriguingly, trabecular parameters showed no relationship with age in this cohort, a dissociation the authors suggest may be linked to higher sclerostin levels in elderly patients, which correlated with stable trabecular architecture.

Lifestyle and metabolic factors left their own signatures on the skeleton. Active or former smokers had lower total and trabecular volumetric bone mineral density in the tibia but not in the radius, consistent with prior evidence that smoking exerts a particularly strong influence on the trabecular compartment. Higher body mass index was associated with greater cortical and trabecular bone areas and higher trabecular density, especially in the radius. The weaker BMI effect in the tibia, a weight-bearing bone where mechanical loading might be expected to matter most, prompted the authors to argue that BMI captures complex systemic processes rather than simple mechanical loading, with detrimental lipotoxic and metabolic pathways potentially counteracting the localized benefits of extra weight at the lower limb.

The biomarker correlations provided some of the most novel insights of the analysis. Sclerostin, a protein secreted by osteocytes that suppresses bone formation, showed a positive correlation with trabecular HR-pQCT parameters, including trabecular volumetric bone mineral density in both the radius and the tibia, an association never before examined in a stroke or TIA population. Higher osteoprotegerin levels were linked to lower cortical area and thickness, echoing findings from the STRAMBO study of men, which similarly showed that elevated osteoprotegerin selectively affects the cortical rather than the trabecular compartment. Osteocalcin, a marker of bone turnover, correlated negatively with total volumetric bone mineral density and cortical thickness in the radius, in line with prior studies linking higher osteocalcin to increased bone turnover and skeletal fragility.

Notably, several traditional cardiovascular risk factors failed to leave any measurable trace on the skeleton in this cohort. No correlation was found between any HR-pQCT parameter and diabetes mellitus, blood pressure, or dyslipidemia, and neither stroke severity at admission nor stroke etiology, classified according to the TOAST criteria, was associated with imaging or biomarker outcomes. When the 17 patients with TIA were excluded to focus on confirmed strokes, the findings remained unchanged, reinforcing the robustness of the observed patterns. Overall, the biochemical markers exerted more influence on bone parameters in the radius than in the tibia, an asymmetry that future longitudinal follow-up may help explain.

The authors are candid about the limitations of their work. The cohort was recruited at a single center, all participants were of European descent, women were underrepresented owing to eligibility criteria such as the exclusion of patients with known osteoporosis, and HR-pQCT measurements were confined to peripheral skeletal sites that may not fully reflect changes in the axial skeleton. The acute phase after stroke may itself perturb biomarker levels, baseline blood sampling was not feasible in all patients, and the exploratory correlation analyses, involving many comparisons without formal adjustment for multiple testing, warrant cautious interpretation. The absence of an in-house, age-matched healthy control group further means the baseline findings describe the absolute bone status of acute patients rather than stroke-specific deviations.

Even so, the study establishes a crucial foundation. By pairing the finest available in vivo images of bone microstructure with a comprehensive biochemical profile gathered within days of a cerebral ischemic event, the Innsbruck team has created the reference point against which future bone loss after stroke can be measured. The prospective design of the Post-stroke Osteopathy study, with follow-up imaging and blood sampling at 3, 6, and 12 months, promises to chart the trajectory of skeletal deterioration and to clarify whether the biomarker signals identified at baseline predict which patients will go on to suffer the devastating fractures that raise mortality and erode quality of life after stroke. If those predictions hold, routine bone microarchitecture screening and early targeted intervention could become standard components of post-stroke care.

Subject of Research: Bone microarchitecture and biomarker characteristics in patients after ischemic stroke or transient ischemic attack assessed with HR-pQCT imaging

Article Title: High-resolution peripheral quantitative computed tomography imaging and bone biomarker characteristics of patients with ischemic stroke or transient ischemic attack—baseline analysis of the Post-stroke Osteopathy study

Article References: Dejakum, B., Bereiter-Payr, J., Felicetti, S., Moelgg, K., Karisik, A., Degenhart, G., Toell, T., Boehme, C., Mayer-Suess, L., Pechlaner, R., Liphardt, A.-M., Berg, G., Schett, G., Kiechl, S., & Knoflach, M. (2026). High-resolution peripheral quantitative computed tomography imaging and bone biomarker characteristics of patients with ischemic stroke or transient ischemic attack—baseline analysis of the Post-stroke Osteopathy study. Archives of Osteoporosis, 21(1), Article 134. https://doi.org/10.1007/s11657-026-01767-w

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01767-w

Keywords: ischemic stroke, transient ischemic attack, HR-pQCT, bone microarchitecture, post-stroke osteopathy, bone biomarkers, osteoporosis, fracture risk, sclerostin, osteoprotegerin, osteocalcin, volumetric bone mineral density